China Biologic Products (CBPO) Getting Somewhat Favorable Media Coverage, Study Finds

Headlines about China Biologic Products (NASDAQ:CBPO) have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. China Biologic Products earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 47.1612463996693 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of China Biologic Products (CBPO) traded up $0.59 on Thursday, hitting $85.05. The stock had a trading volume of 190,358 shares, compared to its average volume of 246,246. China Biologic Products has a 12-month low of $72.21 and a 12-month high of $122.19. The stock has a market cap of $2,330.00, a price-to-earnings ratio of 19.28, a PEG ratio of 1.42 and a beta of 1.71.

CBPO has been the subject of several analyst reports. BidaskClub lowered China Biologic Products from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Jefferies Group LLC reiterated a “buy” rating on shares of China Biologic Products in a report on Friday, August 4th. Finally, Zacks Investment Research upgraded China Biologic Products from a “sell” rating to a “hold” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $137.50.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://stocknewstimes.com/2017/11/16/china-biologic-products-cbpo-getting-somewhat-favorable-media-coverage-study-finds.html.

About China Biologic Products

Insider Buying and Selling by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply